A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities

NCT06672939 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

125

Enrollment

INDUSTRY

Sponsor class

Conditions

Obesity
Overweight

Interventions

DRUG: Orforglipron
DRUG: Placebo

Sponsor

Eli Lilly and Company